Loading...
XNASGRFS
Market cap7.24bUSD
Dec 20, Last price  
7.51USD
1D
-2.72%
1Q
-16.09%
Jan 2017
-53.27%
IPO
17.34%
Name

Grifols SA

Chart & Performance

D1W1MN
XNAS:GRFS chart
P/E
89.76
P/S
0.81
EPS
0.08
Div Yield, %
0.00%
Shrs. gr., 5y
-0.16%
Rev. gr., 5y
8.00%
Revenues
6.59b
+8.71%
524,277,000648,797,000703,291,000814,311,000913,186,000990,730,0001,795,613,0002,620,944,0002,741,732,0003,355,384,0003,934,563,0004,049,830,0004,318,073,0004,486,724,0005,098,691,0005,340,038,0004,933,118,0006,063,967,0006,591,977,000
Net income
59m
-71.52%
25,556,00045,394,00087,774,000121,728,000147,972,000115,513,00050,307,000256,686,000345,551,000470,253,000532,145,000545,456,000662,700,000596,642,000625,146,000618,546,000265,327,000208,279,00059,315,000
CFO
208m
P
119,724,00049,076,00088,644,00073,409,00088,180,000104,252,000220,228,000507,118,000592,011,000978,928,000742,778,000553,278,000841,746,000737,428,000568,933,0001,110,336,000596,975,000-10,867,000208,283,000
Dividend
Jun 03, 20210.4385 USD/sh
Earnings
Feb 26, 2025

Profile

Grifols, S.A. engages in the procurement, manufacture, preparation, and sale of therapeutic products, primarily hemoderivatives. The company operates through Bioscience, Hospital, Diagnostic, Bio Supplies, and Others divisions. The Bioscience division researches, develops, produces, and markets plasma-derived medicines and other innovative solutions to treat patients with chronic, rare, prevalent, and life-threatening diseases. It offers immunoglobulins, alpha-1 antitrypsin, albumin, clotting factors, and hyperimmune globulins. The Hospital division offers non-biological pharmaceutical products and medical supplies clinical nutrition, intravenous therapy, and medical devices. The Diagnostic division researches, develops, produces, and commercializes diagnostic products that span the healthcare continuum–from prevention, screening, diagnosis, and prognosis to disease and treatment monitoring–to serve professionals. The Bio Supplies division provides biological materials for life-science research, clinical trials, and for manufacturing pharmaceutical and diagnostic products. Its products and services are used by healthcare providers to diagnose and treat patients with hemophilia, immune deficiencies, infectious diseases, and other medical conditions. The company serves public and private customers; and wholesalers, distributors, group purchasing organizations, blood banks, hospitals and care institutions, and national health systems. Grifols, S.A. has a technology collaboration agreement with Mondragon. The company was founded in 1940 and is headquartered in Barcelona, Spain.
URL
https://www.grifols.com/
IPO date
May 17, 2006
Employees
23,631
Domiciled in
ES
Incorporated in
ES

Valuation

Title
EUR in thousands, except ratios and share amounts
FYFYFYFYFYFYFYFYFYFY
2023‑122022‑122021‑122020‑122019‑122018‑122017‑122016‑122015‑122014‑12
Income
Revenues
6,591,977
8.71%
6,063,967
22.92%
4,933,118
-7.62%
Cost of revenue
5,854,061
5,384,000
4,386,911
Unusual Expense (Income)
NOPBT
737,916
679,967
546,207
NOPBT Margin
11.19%
11.21%
11.07%
Operating Taxes
43,349
90,111
85,126
Tax Rate
5.87%
13.25%
15.58%
NOPAT
694,567
589,856
461,081
Net income
59,315
-71.52%
208,279
-21.50%
265,327
-57.10%
Dividends
(592)
(258,946)
Dividend yield
Proceeds from repurchase of equity
(3,459)
(125,703)
BB yield
Debt
Debt current
897,915
681,273
2,394,182
Long-term debt
10,330,852
10,085,796
7,803,848
Deferred revenue
13,807
15,123
15,036
Other long-term liabilities
930,814
1,001,788
33,344
Net debt
10,017,942
7,626,942
5,153,455
Cash flow
Cash from operating activities
208,283
(10,867)
596,975
CAPEX
(209,538)
(375,560)
(315,088)
Cash from investing activities
(397,636)
(1,978,823)
(29,393)
Cash from financing activities
186,045
(173,493)
1,472,923
FCF
(968,909)
(1,260,117)
(75,385)
Balance
Cash
645,720
591,235
2,684,600
Long term investments
565,105
2,548,892
2,359,975
Excess cash
881,226
2,836,929
4,797,919
Stockholders' equity
7,214,505
8,619,764
8,311,224
Invested Capital
18,153,510
16,352,845
12,697,008
ROIC
4.03%
4.06%
3.84%
ROCE
3.69%
3.36%
3.01%
EV
Common stock shares outstanding
679,092
678,411
678,540
Price
Market cap
EV
EBITDA
1,179,834
1,087,831
905,974
EV/EBITDA
Interest
596,864
362,629
233,813
Interest/NOPBT
80.89%
53.33%
42.81%